TITLE

DNA-guided hepatitis B treatment, viral load is essential, but not sufficient

AUTHOR(S)
Marugán, Rafael Bárcena; Garzón, Silvia García
PUB. DATE
January 2009
SOURCE
World Journal of Gastroenterology;1/28/2009, Vol. 15 Issue 4, p423
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hepatitis B virus (HBV) infection is a global public health problem that concerns 350 million people worldwide. Individuals with chronic hepatitis B (CHB) are at increased risk of developing liver cirrhosis, hepatic de-compensation and hepatocellular carcinoma. To maintain undetectable viral load reduces chronic infection complications. There is no treatment that eradicates HBV infection. Current drugs are expensive, are associated with adverse events, and are of limited efficacy. Current guidelines try to standardize the clinical practice. Nevertheless, controversy remains about management of asymptomatic patients with CHB who are hepatitis B e antigen (HBeAg)-positive with normal alanine aminotransferase, and what is the cut-off value of viral load to distinguish HBeAg-negative CHB patients and inactive carriers. We discuss in detail why DNA level alone is not sufficient to begin treatment of CHB.
ACCESSION #
36633598

 

Related Articles

  • Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. Lee, Hye Won; Yoo, Eun Jin; Kim, Beom Kyung; Kim, Seung Up; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang-Hyub // American Journal of Gastroenterology;Aug2014, Vol. 109 Issue 8, p1241 

    OBJECTIVES:In the era of antiviral therapy, the prognostic significance of serum hepatitis B virus (HBV) DNA level as a biological gradient substantially diminished, as most patients can achieve complete virological response (CVR). We aimed to investigate the predictive roles of liver stiffness...

  • A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China. Tao-Tao Liu; Ying Fang; Hui Xiong; Tao-Yang Chen; Zheng-Pin Ni; Jian-Feng Luo; Nai-Qing Zhao; Xi-Zhong Shen; Xin-Xin Zhang // World Journal of Gastroenterology;5/21/2008, Vol. 14 Issue 19, p3059 

    AIM: To investigate the role of hepatitis B virus (HBV) replication in the development of hepatocellular carcinoma (HCC), a nested case-control study was performed to study the relationship between HBV DNA level and risk of HCC. METHODS: One hundred and seventy cases of HCC and 276 control...

  • Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with Lamivudine. Gauthier, Josee; Bourne, Eric J.; Lutz, Michael W.; Crowther, Lynn M.; Dienstag, Jules L.; Brown, Nathaniel A. // Journal of Infectious Diseases;12/1/99, Vol. 180 Issue 6, p1757 

    Hepatitis B viremia and emergence of hepatitis B virus (HBV) YMDDvariants with reduced susceptibility to lamivudine were analyzed in patient sera from a phase II study of extended lamivudine therapy. Within 12 weeks, all patients exhibited a marked virologic response to lamivudine: >99%...

  • Reasons to consider earlier treatment of chronic HBV infections. Zoulim, Fabien; Mason, William S. // Gut;Mar2012, Vol. 61 Issue 3, p333 

    The article discusses the reasons to consider earlier for the treatment of chronic hepatitis B virus (HBV) infections. It states that cirrhosis, liver failure and hepatocellular carcinoma (HCC) diseases are caused by the HBV infection which occur at the early stage of life. It also informs that...

  • Management of chronic hepatitis B infection. Davison, Suzanne // Archives of Disease in Childhood;Nov2014, Vol. 99 Issue 11, p1037 

    The spectrum of chronic hepatitis B infection in children ranges from asymptomatic carriage with minimal disease, to progression to cirrhosis and risk of hepatocellular carcinoma in adulthood. Identifying those who will benefit from treatment is a challenge. Interferon-based therapies have...

  • Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance. Kobayashi, Mariko; Chayama, Kazuaki; Arase, Yasuji; Tsubota, Akihito; Saitoh, Satoshi; Suzuki, Yoshiyuki; Kobayashi, Masahiro; Murashima, Naoya; Ikeda, Kenji; Hagiwara, Mika; Hashimoto, Rie; Nakagawa, Miki; Matsuda, Marie; Kumada, Hiromitsu // Journal of Gastroenterology;2000, Vol. 35 Issue 10, p753 

    Abstract: The aim of this study was to elucidate the relationships among serum levels of hepatitis B virus (HBV) DNA, periods after hepatitis B surface (HBs) antigen clearance, and the titer of hepatitis B core (HBc) antibody in 200-fold diluted serum. Twelve patients who had clearance of HBs...

  • Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. Chen, Chien-Jen; Yang, Hwai-I.; Su, Jun; Jen, Chin-Lan; You, v; Lu, Sheng-Nan; Huang, Guan-Tarn; Iloeje, Uchenna H. // JAMA: Journal of the American Medical Association;1/4/2006, Vol. 295 Issue 1, p65 

    t: Serum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B. Objective: To evaluate the relationship between serum HBV DNA level and risk of hepatocellular carcinoma. Design, Setting, and Participants:...

  • Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Liu, Jessica; Hwai-I Yang; Mei-Hsuan Lee; Sheng-Nan Lu; Chin-Lan Jen; Batrla-Utermann, Richard; Li-Yu Wang; San-Lin You; Chuhsing K. Hsiao; Pei-Jer Chen; Chien-Jen Chen // Gut;Oct2014, Vol. 63 Issue 10, p1648 

    Background and aims The associations between long-term risk of hepatocellular carcinoma (HCC) and spontaneous seroclearance of HBV e antigen (HBeAg), HBV DNA and HBV surface antigen (HBsAg) have never been examined by a prospective study using serially measured seromarkers. This study aimed to...

  • Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer Il/core promoter/precore regions and HBV DNA levels. Yuen, M-F; Tanaka, Y.; Shinkai, N.; Poon, R. T.; But, D. Yiu-Kuen; Fong, D Y-T; Fung, J; Ka-Ho Wang, D; Chi-Hang Yuen, J; Mizokami, M; Lai, C-L // Gut;Jan2008, Vol. 57 Issue 1, p98 

    Background/aim: To examine the risks for hepatocellular carcinoma (HCC) with respect to hepatitis B virus (HBV) genotypes, specific viral mutations (MT), serum HBV DNA levels, and cirrhosis. Methods: HBV genotypes, 1653/1753/core promoter (CP)/precore MT and HBV DNA levels were determined in 248...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics